Plant Name: Oryza sativa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| OPRD1; | |
| PTPN1; | |
| GAA; | |
| TDP1; LSS; AKR1B10; AKR1B1; HSD17B10; ALDH1A1; BRCA1; APEX1; | |
| KDR; AURKB; AURKA; | |
| CA2; CA1; CA12; CA9; CA7; CA3; CA14; CA5B; CA5A; CA4; CA6; | |
| ESR2; | |
| MMP1; MMP2; MMP9; | |
| NFKB1; | |
| SLCO1B3; SLCO1B1; | |
| HTT; LMNA; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | LSS | Lanosterol synthase | P48449 | CHEMBL3593 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.276E-12 | 2.779E-09 | BRCA1, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, MMP1, MMP2, MMP9, PTPN1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.222E-07 | 1.774E-04 | CYP1A1, CYP1B1, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 1.399E-07 | 1.904E-04 | AKR1B1, APEX1, CYP1B1, KDR, NFKB1, OPRD1 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 5.572E-07 | 5.778E-04 | AKR1B1, AKR1B10, CYP1A1, CYP1B1, CYP2D6, CYP3A4, LSS |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 8.210E-07 | 7.773E-04 | AKR1B1, APEX1, AURKA, BRCA1, CA2, CA9, CYP1B1, LMNA, MAPT, MMP9, NFKB1, OPRD1, PTPN1, TDP1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.522E-28 | 1.420E-23 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.991E-06 | 1.606E-03 | CYP1A1, CYP1B1, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 2.463E-06 | 1.916E-03 | AKR1B1, ALDH1A1, CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 5.961E-06 | 4.056E-03 | APEX1, CYP1A1, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 8.331E-06 | 5.183E-03 | AKR1B1, AKR1B10, ALDH1A1, APEX1, CYP1A1, CYP1B1, CYP2D6, CYP3A4, GAA, HSD17B10 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.190E-05 | 6.479E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.190E-05 | 6.479E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.190E-05 | 6.479E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 1.998E-05 | 9.257E-03 | AKR1B1, APEX1, BRCA1, CYP1B1, KDR, NFKB1 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.526E-21 | 3.839E-17 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.845E-20 | 3.417E-16 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.023E-27 | 4.103E-25 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.220E-05 | 4.146E-04 | CYP2D6; CYP1A1; CYP1B1; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.092E-05 | 4.146E-04 | SLCO1B1; CA2; SLCO1B3; CYP3A4 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 6.942E-05 | 1.416E-03 | MMP1; MMP2; MMP9 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.684E-05 | 6.843E-04 | AKR1B10; GAA; AKR1B1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.964E-04 | 3.339E-03 | CYP1A1; CYP1B1; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.754E-04 | 4.013E-03 | ALDH1A1; CYP1A1; CYP3A4 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 9.447E-04 | 9.636E-03 | MMP2; MMP9; ESR2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.458E-04 | 6.958E-03 | CYP1A1; CYP1B1; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.329E-03 | 1.827E-02 | AKR1B10; GAA; ALDH1A1; CYP1A1; AKR1B1; CYP3A4; HSD17B10; LSS |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.604E-03 | 1.875E-02 | CYP1B1; BRCA1; MMP9; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.270E-03 | 3.903E-02 | MMP1; MMP2; MMP9; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 7.197E-03 | 3.903E-02 | MMP2; KDR; MMP9 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.239E-03 | 1.827E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 9.135E-04 | 9.636E-03 | CA2; CA4 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.278E-03 | 2.728E-02 | CYP1A1; CYP1B1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.758E-03 | 1.875E-02 | CYP1A1; CYP1B1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 5.910E-03 | 3.546E-02 | AKR1B10; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.771E-03 | 1.642E-02 | AKR1B10; AKR1B1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 8.690E-03 | 4.221E-02 | NFKB1; ESR2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 8.005E-03 | 4.083E-02 | CYP2D6; CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | KDR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | LSS |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | AURKA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1; MMP1; AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | AML | NA | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | AURKA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRD1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | OPRD1; CYP3A4 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; AURKA |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1 |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; KDR; KDR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1 |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; MMP9; NFKB1; MMP2; KDR; AURKA |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; KDR |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; KDR; KDR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; MMP9; MMP2; KDR; KDR; KDR; AURKB; AURKA |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |